Applied dna enters into agreement with alphazyme for scale-up manufacturing of its proprietary linea(tm) rnap, progresses towards gmp linea(tm) ivt production start

- project to increase rnap manufacturing capacity and reduce unit costs of goods - - project slated for completion coincident with company's planned initiation of gmp manufacturing for linea ™ dna ivt templates - stony brook, ny and jupiter, fl / accesswire / march 18, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna or the company), a leader in pcr-based dna technologies, and alphazyme llc (alphazyme), a maravai lifesciences company (mrvi) and global provider of specialty enzymes used in the life sciences sector, have entered into an agreement under which alphazyme will scale-up manufacturing of applied dna's proprietary linea™ rna polymerase ("rnap"). under the terms of the agreement, alphazyme will perform manufacturing process development, enabling the scaling of linea rnap manufacturing from its current research scale to the commercial scale necessary to empower the company's growing demand for the company's linea™ ivt platform.
APDN Ratings Summary
APDN Quant Ranking